<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.36485/1561-6274-2021-25-2-43-51</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-1942</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ И ЛЕКЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS AND LECTURES</subject></subj-group></article-categories><title-group><article-title>Участие ренин-ангиотензин-альдостероновой системы в развитии диабетической нефропатии при сахарном диабете 1 типа (обзор литературы)</article-title><trans-title-group xml:lang="en"><trans-title>The effect of the components of the renin-angiotensinaldosterone system on the development of diabetic nephropathy in type 1 diabetes (review)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9790-3633</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скобелева</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Skobeleva</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аспирант Скобелева Кристина Владимировна</p><p>194100, Россия, Санкт-Петербург, Литовская, д. 2</p><p>Тел.: (812) 542-93-09</p></bio><bio xml:lang="en"><p>Postgraduate student Kristina V. Skobeleva, MD</p><p>194100 Russia, St-Petersburg, Lytovskaya st., 2, St.-Petersburg</p><p>Phone: (812) 542-93-09</p></bio><email xlink:type="simple">skobeleva_kv@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4417-1373</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тыртова</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tyrtova</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Проф. Тыртова Людмила Викторовна</p><p>194100, Россия, Санкт-Петербург, Литовская, д. 2</p><p>Тел.: (812) 542-93-09</p></bio><bio xml:lang="en"><p>Prof. Ljudmila V. Tyrtova MD, PhD, DMedSci</p><p>194100 Russia, St-Petersburg, Lytovskaya st., 2, St.-Petersburg</p><p>Phone: (812) 542-93-09</p></bio><email xlink:type="simple">drtyrtova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Санкт-Петербургский государственный педиатрический медицинский университет, кафедра факультетской педиатрии, эндокринологическое отделение</institution><country>Россия</country></aff><aff xml:lang="en"><institution>St.-Petersburg State Pediatric Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>13</day><month>02</month><year>2021</year></pub-date><volume>25</volume><issue>2</issue><fpage>43</fpage><lpage>51</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Скобелева К.В., Тыртова Л.В., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Скобелева К.В., Тыртова Л.В.</copyright-holder><copyright-holder xml:lang="en">Skobeleva K.V., Tyrtova L.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/1942">https://journal.nephrolog.ru/jour/article/view/1942</self-uri><abstract><p>Одна из ключевых ролей в развитии диабетической нефропатии (ДН) принадлежит ренин-ангиотензинальдостероновой системе (РААС), которая участвует в регуляции гемодинамики, системного и внутрипочечного давления, продукции профиброгенных и ростовых факторов, ремоделировании сосудов. В конце ХХ века были обнаружены локальные (тканевые) элементы РААС от ренина до альдостерона непосредственно в тканях и органах-мишенях (в том числе в почках). Тканевым РААС отводят ведущую роль в развитии сосудистых осложнений сахарного диабета (СД): сердечно-сосудистой патологии, диабетической нефропатии и ретинопатии. Именно это обстоятельство объясняет во многом патогенетическую роль РААС в поражении органов-мишеней даже при нормальной или низкой активности ренина плазмы (АРП) [<xref ref-type="bibr" rid="cit1">1</xref>]. Установлено, что активация РААС происходит задолго до появления клинических признаков ДН, что дает возможность для более ранней профилактики и коррекции начальных изменений при исследовании ее компонентов, а также снижения инвалидизации и выхода пациентов в хроническую болезнь почек. Учитывая тенденцию к «омоложению» сахарного диабета, лабильность течения заболевания в детском возрасте, высокую гормональную активность у данной группы пациентов и, следовательно, больший риск развития осложнений, своевременная диагностика начальных проявлений ДН имеет высокую актуальность и востребованность.</p></abstract><trans-abstract xml:lang="en"><p>One of the key roles in the development of diabetic nephropathy belongs to the renin-angiotensin-aldosterone system (RAAS), which is involved in the regulation of hemodynamics, systemic and intrarenal pressure, production of profibrogenic and growth factors, vascular remodeling. At the end of the twentieth century, local (tissue) RAAS elements from renin to aldosterone were found in tissues and target organs (including kidneys). Tissue RAAS plays a leading role in the development of vascular complications of diabetes mellitus (DM): cardiovascular disease, diabetic nephropathy, and retinopathy. It is this fact that explains in many ways the pathogenetic role of RAAS in the defeat of target organs even with normal or low plasma renin activity (ARP). RAAS activation occurs long before the clinical signs of diabetic nephropathy, which makes it possible for earlier prevention and correction of initial changes in the study of its components, as well as reducing disability and the output of patients in chronic kidney disease. Given the tendency to “rejuvenate” diabetes mellitus, the lability of the course of the disease in childhood, the high hormonal activity in this group of patients, and, therefore, the greater the risk of complications, the timely diagnosis of the initial manifestations of DN is of high relevance and relevance.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ренин-ангиотензин-альдостероновая система</kwd><kwd>сахарный диабет 1-го типа</kwd><kwd>гипергликемия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>renin-angiotensin-aldosterone system</kwd><kwd>type 1 diabetes</kwd><kwd>hyperglycemia</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Шестакова МВ. Роль тканевой ренин-ангиотензинальдостероновой системы в развитии метаболического синдрома, сахарного диабета и его сосудистых осложнений (пленарная лекция). Сахарный диабет 3/2010; 14-19</mixed-citation><mixed-citation xml:lang="en">Shestakova MV. The Role of tissue renin-angiotensin-aldosterone system in the development of metabolic syndrome, diabetes mellitus and its vascular complications (plenary lecture). Diabetes Mellitus 3/2010; 14-19</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">International Diabetes Federation. Диабетический атлас 9-е издание, 2019</mixed-citation><mixed-citation xml:lang="en">International Diabetes Federation. Диабетический атлас 9-е издание, 2019</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Шестакова МВ, Викулова ОК, Железнякова АВ и др. Эпидемиология сахарного диабета в Российской Федерации: что изменилось за последнее десятилетие? Терапевтический архив 2019; 91(10): 4–13. doi: 10.26442/00403660.2019.10.000364</mixed-citation><mixed-citation xml:lang="en">Shestakova MV, Vikulova OK, Zheleznyakova AV and others. Epidemiology of diabetes in the Russian Federation: what has changed over the past decade? Therapeutic archive 2019; 91(10): 4–13. doi 10.26442/00403660.2019.10.000364</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов ИИ, Шестакова МВ, Петеркова ВА и др. Сахарный диабет у детей и подростков по данным Федерального регистра Российской Федерации: динамика основных эпидемиологических характеристик за 2013–2016 гг. Сахарный диабет 2017;20(6):392-402</mixed-citation><mixed-citation xml:lang="en">Dedov I and others. Diabetes mellitus in children and adolescents according to the Federal register of the Russian Federation: dynamics of the main epidemiological characteristics for 2013–2016. Diabetes Mellitus 2017;20(6):392-402</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Van Raalte DH, Bjornstad P. Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes. Nephrol Dial Transplant 2020 Jan 1;35(Suppl 1):i24-i32. doi: 10.1093/ndt/gfz228. PMID: 32003832; PMCID: PMC6993198</mixed-citation><mixed-citation xml:lang="en">Van Raalte DH, Bjornstad P. Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes. Nephrol Dial Transplant 2020 Jan 1;35(Suppl 1):i24-i32. doi: 10.1093/ndt/gfz228. PMID: 32003832; PMCID: PMC6993198</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Miller RG, Mahajan HD, Costacou T et al. A contemporary estimate of total mortality and cardiovascular disease risk in young adults with type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2016; 39: 2296–2303</mixed-citation><mixed-citation xml:lang="en">Miller RG, Mahajan HD, Costacou T et al. A contemporary estimate of total mortality and cardiovascular disease risk in young adults with type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2016; 39: 2296–2303</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Harding JL, Shaw JE, Peeters A et al. Age-specific trends from 2000–2011 in all-cause and cause-specific mortality in type 1 and type 2 diabetes: a cohort study ofmore than one million people. Diabetes Care 2016; 39: 1018–1026</mixed-citation><mixed-citation xml:lang="en">Harding JL, Shaw JE, Peeters A et al. Age-specific trends from 2000–2011 in all-cause and cause-specific mortality in type 1 and type 2 diabetes: a cohort study ofmore than one million people. Diabetes Care 2016; 39: 1018–1026</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">WHO/IDF, Report: "Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia», 2007;</mixed-citation><mixed-citation xml:lang="en">WHO/IDF, Report: "Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia», 2007;</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов ИИ. Алгоритмы специализированной медицинской помощи больным сахарным диабетом, 8-й выпуск, М., 2017; 39-44</mixed-citation><mixed-citation xml:lang="en">Dedov I. Algorithms of specialized medical care for diabetic patients, issue 8, Moscow, 2017; 39-44. doi: 10.14341/DM20171S8</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Donate-Correa J, Luis-Rodríguez D, Martín-Núñez E, Tagua VG, Hernández-Carballo C, Ferri C, Rodríguez-Rodríguez AE, Mora-Fernández C, Navarro-González JF. Inflammatory Targets in Diabetic Nephropathy. J Clin Med 2020 Feb 7;9(2):458. doi: 10.3390/jcm9020458. PMID: 32046074; PMCID: PMC7074396</mixed-citation><mixed-citation xml:lang="en">Donate-Correa J, Luis-Rodríguez D, Martín-Núñez E, Tagua VG, Hernández-Carballo C, Ferri C, Rodríguez-Rodríguez AE, Mora-Fernández C, Navarro-González JF. Inflammatory Targets in Diabetic Nephropathy. J Clin Med 2020 Feb 7;9(2):458. doi: 10.3390/jcm9020458. PMID: 32046074; PMCID: PMC7074396</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Patel DM, Bose M, Cooper ME. Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease. Int J Mol Sci 2020 Mar 23;21(6):2218. doi: 10.3390/ijms21062218. PMID: 32210089; PMCID: PMC7139394</mixed-citation><mixed-citation xml:lang="en">Patel DM, Bose M, Cooper ME. Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease. Int J Mol Sci 2020 Mar 23;21(6):2218. doi: 10.3390/ijms21062218. PMID: 32210089; PMCID: PMC7139394</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Nektaria Papadopoulou Marketou, Chrousos GP, Kanaka-Gantenbein C. Diabetic nephropathy in type 1 diabetes: a review of early natural history, pathogenesis, and diagnosis. Diabetes Metab Res Rev 2017 Feb;33(2). doi: 10.1002/dmrr.2841. Epub 2016 Oct 4. PMID: 27457509</mixed-citation><mixed-citation xml:lang="en">Nektaria Papadopoulou Marketou, Chrousos GP, Kanaka-Gantenbein C. Diabetic nephropathy in type 1 diabetes: a review of early natural history, pathogenesis, and diagnosis. Diabetes Metab Res Rev 2017 Feb;33(2). doi: 10.1002/dmrr.2841. Epub 2016 Oct 4. PMID: 27457509</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Aasem Saif, Neveen Soliman. Urinary α1-microglobulin and albumin excretion in children and adolescents with type 1 diabetes. Journal of Diabetes 2017; 9: 61-64</mixed-citation><mixed-citation xml:lang="en">Aasem Saif, Neveen Soliman. Urinary α1-microglobulin and albumin excretion in children and adolescents with type 1 diabetes. Journal of Diabetes 2017; 9: 61-64</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Dugbartey GJ. Diabetic nephropathy: A potential savior with 'rotten-egg' smell. Pharmacol Rep 2017 Apr;69(2):331-339. doi: 10.1016/j.pharep.2016.11.004. Epub 2016 Nov 11. PMID: 28183033</mixed-citation><mixed-citation xml:lang="en">Dugbartey GJ. Diabetic nephropathy: A potential savior with 'rotten-egg' smell. Pharmacol Rep 2017 Apr;69(2):331-339. doi: 10.1016/j.pharep.2016.11.004. Epub 2016 Nov 11. PMID: 28183033</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ma M, Wan X, Gao M et al. Renin-angiotensin-aldosterone system blockade is associated with higher risk of contrast-induced acute kidney injury in patients with diabetes. Aging (Albany NY). 2020 Apr 2;12(7):5858-5877. doi: 10.18632/aging.102982. Epub 2020 Apr 2. PMID: 32241961; PMCID: PMC7185147</mixed-citation><mixed-citation xml:lang="en">Ma M, Wan X, Gao M et al. Renin-angiotensin-aldosterone system blockade is associated with higher risk of contrast-induced acute kidney injury in patients with diabetes. Aging (Albany NY). 2020 Apr 2;12(7):5858-5877. doi: 10.18632/aging.102982. Epub 2020 Apr 2. PMID: 32241961; PMCID: PMC7185147</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Daniels M, DuBose SN, Maahs DM et al. T1D Exchange Clinic Network. Factors associated with microalbuminuria in 7,549 children and adolescents with type 1 diabetes in the T1D Exchange clinic registry. Diabetes Care 2013 Sep;36(9):2639-2645. doi: 10.2337/dc12-2192. Epub 2013 Apr 22. PMID: 23610082; PMCID: PMC3747908</mixed-citation><mixed-citation xml:lang="en">Daniels M, DuBose SN, Maahs DM et al. T1D Exchange Clinic Network. Factors associated with microalbuminuria in 7,549 children and adolescents with type 1 diabetes in the T1D Exchange clinic registry. Diabetes Care 2013 Sep;36(9):2639-2645. doi: 10.2337/dc12-2192. Epub 2013 Apr 22. PMID: 23610082; PMCID: PMC3747908</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Fu H, Liu S, Bastacky SI et al. Diabetic kidney diseases revisited: A new perspective for a new era. Mol Metab 2019 Dec;30:250-263. doi: 10.1016/j.molmet.2019.10.005. Epub 2019 Oct 17. PMID: 31767176; PMCID: PMC6838932</mixed-citation><mixed-citation xml:lang="en">Fu H, Liu S, Bastacky SI et al. Diabetic kidney diseases revisited: A new perspective for a new era. Mol Metab 2019 Dec;30:250-263. doi: 10.1016/j.molmet.2019.10.005. Epub 2019 Oct 17. PMID: 31767176; PMCID: PMC6838932</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Leehey David J, Singh Ashok K, Singh Rekha. Angiotensin II and Its Receptors in the Pathogenesis of Diabetic Nephropathy, From: Contemporary Diabetes: The Diabetic Kidney. doi. org/10.1007/978-1-59745-153-6-1</mixed-citation><mixed-citation xml:lang="en">Leehey David J, Singh Ashok K, Singh Rekha. Angiotensin II and Its Receptors in the Pathogenesis of Diabetic Nephropathy, From: Contemporary Diabetes: The Diabetic Kidney. doi. org/10.1007/978-1-59745-153-6-1</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang H, Zuo JJ, Dong SS et al. Identification of Potential Serum Metabolic Biomarkers of Diabetic Kidney Disease: A Widely Targeted Metabolomics Study. J Diabetes Res 2020 Mar 2;2020:3049098. doi: 10.1155/2020/3049098. PMID: 32190695; PMCID: PMC7072115</mixed-citation><mixed-citation xml:lang="en">Zhang H, Zuo JJ, Dong SS et al. Identification of Potential Serum Metabolic Biomarkers of Diabetic Kidney Disease: A Widely Targeted Metabolomics Study. J Diabetes Res 2020 Mar 2;2020:3049098. doi: 10.1155/2020/3049098. PMID: 32190695; PMCID: PMC7072115</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Antônio Ribeiro-Oliveira Jr, Anelise Impeliziere Nogueira, Regina Maria Pereira et al. The renin–angiotensin system and diabetes: An update, Vascular Health and Risk Management 2008:4(4) 787–803</mixed-citation><mixed-citation xml:lang="en">Antônio Ribeiro-Oliveira Jr, Anelise Impeliziere Nogueira, Regina Maria Pereira et al. The renin–angiotensin system and diabetes: An update, Vascular Health and Risk Management 2008:4(4) 787–803</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Zubair Ilyas, Chaiban JT, Krikorian A. Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy. Rev Endocr Metab Disord 2017 Mar;18(1):21-28. doi: 10.1007/s11154-017-9422-3. PMID: 28289965.</mixed-citation><mixed-citation xml:lang="en">Zubair Ilyas, Chaiban JT, Krikorian A. Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy. Rev Endocr Metab Disord 2017 Mar;18(1):21-28. doi: 10.1007/s11154-017-9422-3. PMID: 28289965.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Куценко ЛВ, Зорин ИВ, Вялкова АА. Патогенетические механизмы формирования нефропатии при сахарном диабете 1 типа: обзор литературы. Лечащий врач 2018;6:58-61</mixed-citation><mixed-citation xml:lang="en">Kutsenko LV, Zorin IV, Vyalkova AA. Pathogenetic mechanisms of the formation of nephropathy in type 1 diabetes mellitus: a literature review. Lechaschi Vrach Journal 2018; 6:58-61</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Campbell KN, Raij L, Mundel P. Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes. Curr Diabetes Rev 2011 Jan;7(1):3-7. doi: 10.2174/157339911794273973. PMID: 21067505; PMCID: PMC3690294</mixed-citation><mixed-citation xml:lang="en">Campbell KN, Raij L, Mundel P. Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes. Curr Diabetes Rev 2011 Jan;7(1):3-7. doi: 10.2174/157339911794273973. PMID: 21067505; PMCID: PMC3690294</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Fouad M, Salem I, Elhefnawy K, Raafat N, Faisal A. MicroRNA- 21 as an Early Marker of Nephropathy in Patients with Type 1 Diabetes. Indian J Nephrol 2020 Jan-Feb; 30(1):21-25. doi: 10.4103/ijn.IJN_80_19. Epub 2019 Dec 27. PMID: 32015595; PMCID: PMC6977383</mixed-citation><mixed-citation xml:lang="en">Fouad M, Salem I, Elhefnawy K, Raafat N, Faisal A. MicroRNA- 21 as an Early Marker of Nephropathy in Patients with Type 1 Diabetes. Indian J Nephrol 2020 Jan-Feb; 30(1):21-25. doi: 10.4103/ijn.IJN_80_19. Epub 2019 Dec 27. PMID: 32015595; PMCID: PMC6977383</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Patricia C Underwood, Gail K. Adler. The Renin Angiotensin Aldosterone System and Insulin Resistance in Humans. Curr Hypertens Rep 2013 February; 15(1): 59–70. doi:10.1007/s11906-012-0323-2</mixed-citation><mixed-citation xml:lang="en">Patricia C Underwood, Gail K. Adler. The Renin Angiotensin Aldosterone System and Insulin Resistance in Humans. Curr Hypertens Rep 2013 February; 15(1): 59–70. doi:10.1007/s11906-012-0323-2</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Guillaume A. Favre, Vincent L. M. Esnault, Emmanuel Van Obberghen. Modulation of glucose metabolism by the reninangiotensin- aldosterone system. Am J Physiol Endocrinol Metab 2015; 308: E435–E449, doi:10.1152/ajpendo.00391.2014</mixed-citation><mixed-citation xml:lang="en">Guillaume A. Favre, Vincent L. M. Esnault, Emmanuel Van Obberghen. Modulation of glucose metabolism by the reninangiotensin- aldosterone system. Am J Physiol Endocrinol Metab 2015; 308: E435–E449, doi:10.1152/ajpendo.00391.2014</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Jha JC, Banal C, Chow BS et al. Diabetes and Kidney Disease: Role of Oxidative Stress. Antioxid Redox Signal 2016 Oct 20;25(12):657-684. doi: 10.1089/ars.2016.6664. Epub 2016 Apr 1. PMID: 26906673; PMCID: PMC5069735</mixed-citation><mixed-citation xml:lang="en">Jha JC, Banal C, Chow BS et al. Diabetes and Kidney Disease: Role of Oxidative Stress. Antioxid Redox Signal 2016 Oct 20;25(12):657-684. doi: 10.1089/ars.2016.6664. Epub 2016 Apr 1. PMID: 26906673; PMCID: PMC5069735</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Pickering RJ, Tikellis C, Rosado CJ et al. Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis. J Clin Invest 2019 Jan 2;129(1):406-421. doi: 10.1172/JCI99987. Epub 2018 Dec 10. PMID: 30530993; PMCID: PMC6307942</mixed-citation><mixed-citation xml:lang="en">Pickering RJ, Tikellis C, Rosado CJ et al. Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis. J Clin Invest 2019 Jan 2;129(1):406-421. doi: 10.1172/JCI99987. Epub 2018 Dec 10. PMID: 30530993; PMCID: PMC6307942</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ranganath Muniyappa, Shazene Yavuz. Metabolic Actions of Angiotensin II and Insulin: A Microvascular Endothelial Balancing Act. Mol Cell Endocrinol 2013, September 25; 378(0): 59–69. doi:10.1016/j.mce.2012.05.017</mixed-citation><mixed-citation xml:lang="en">Ranganath Muniyappa, Shazene Yavuz. Metabolic Actions of Angiotensin II and Insulin: A Microvascular Endothelial Balancing Act. Mol Cell Endocrinol 2013, September 25; 378(0): 59–69. doi:10.1016/j.mce.2012.05.017</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Frimodt-Møller M, Persson F, Rossing P. Mitigating risk of aldosterone in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2020 Jan;29(1):145-151. doi: 10.1097/MNH.0000000000000557. PMID: 31599747; PMCID: PMC6903382</mixed-citation><mixed-citation xml:lang="en">Frimodt-Møller M, Persson F, Rossing P. Mitigating risk of aldosterone in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2020 Jan;29(1):145-151. doi: 10.1097/MNH.0000000000000557. PMID: 31599747; PMCID: PMC6903382</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Nishiyama A, Kobori H. Independent regulation of reninangiotensin-aldosterone system in the kidney. Clin Exp Nephrol 2018 Dec;22(6):1231-1239. doi: 10.1007/s10157-018-1567-1. Epub 2018 Mar 29. PMID: 29600408; PMCID: PMC6163102</mixed-citation><mixed-citation xml:lang="en">Nishiyama A, Kobori H. Independent regulation of reninangiotensin-aldosterone system in the kidney. Clin Exp Nephrol 2018 Dec;22(6):1231-1239. doi: 10.1007/s10157-018-1567-1. Epub 2018 Mar 29. PMID: 29600408; PMCID: PMC6163102</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Oppelaar JJ, Vogt L. Body Fluid-Independent Effects of Dietary Salt Consumption in Chronic Kidney Disease. Nutrients 2019 Nov 15;11(11):2779. doi: 10.3390/nu11112779. PMID: 31731658; PMCID: PMC6893804</mixed-citation><mixed-citation xml:lang="en">Oppelaar JJ, Vogt L. Body Fluid-Independent Effects of Dietary Salt Consumption in Chronic Kidney Disease. Nutrients 2019 Nov 15;11(11):2779. doi: 10.3390/nu11112779. PMID: 31731658; PMCID: PMC6893804</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Sousa AG, Cabral JV, El-Feghaly WB, de Sousa LS, Nunes AB. Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management. World J Diabetes 2016;7(5):101-111. doi:10.4239/wjd.v7.i5.101</mixed-citation><mixed-citation xml:lang="en">Sousa AG, Cabral JV, El-Feghaly WB, de Sousa LS, Nunes AB. Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management. World J Diabetes 2016;7(5):101-111. doi:10.4239/wjd.v7.i5.101</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Valabhji J, Donovan J, Kyd P A et al. The relationship between active renin concentration and plasma renin activity in Type 1 diabetes, Diabetes UK. Diabetic Medicine 2001; 18: 451-458</mixed-citation><mixed-citation xml:lang="en">Valabhji J, Donovan J, Kyd P A et al. The relationship between active renin concentration and plasma renin activity in Type 1 diabetes, Diabetes UK. Diabetic Medicine 2001; 18: 451-458</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Bojestig M, Nystrom FH, Arnqvist HJ et al. The reninangiotensin-aldosterone system is suppressed in adults with Type 1 diabetes, JRAAS 2000;1:353-356</mixed-citation><mixed-citation xml:lang="en">Bojestig M, Nystrom FH, Arnqvist HJ et al. The reninangiotensin-aldosterone system is suppressed in adults with Type 1 diabetes, JRAAS 2000;1:353-356</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Garsen M, Rops AL, Dijkman H et al. Cathepsin L is crucial for the development of early experimental diabetic nephropathy. Kidney Int 2016;90(5):1012-1022. doi:10.1016/j.kint.2016.06.035</mixed-citation><mixed-citation xml:lang="en">Garsen M, Rops AL, Dijkman H et al. Cathepsin L is crucial for the development of early experimental diabetic nephropathy. Kidney Int 2016;90(5):1012-1022. doi:10.1016/j.kint.2016.06.035</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Wang J, Shibayama Y, Kobori H et al. High glucose augments angiotensinogen in human renal proximal tubular cells through hepatocyte nuclear factor-5. PLoS One 2017; 12(10):e0185600. Published 2017 Oct 20. doi:10.1371/journal.pone.0185600</mixed-citation><mixed-citation xml:lang="en">Wang J, Shibayama Y, Kobori H et al. High glucose augments angiotensinogen in human renal proximal tubular cells through hepatocyte nuclear factor-5. PLoS One 2017; 12(10):e0185600. Published 2017 Oct 20. doi:10.1371/journal.pone.0185600</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Sato E, Mori T, Satoh M et al. Urinary angiotensinogen excretion is associated with blood pressure in obese young adults. Clin Exp Hypertens 2016;38(2):203-208. doi:10.3109/10641963.2015.1081219</mixed-citation><mixed-citation xml:lang="en">Sato E, Mori T, Satoh M et al. Urinary angiotensinogen excretion is associated with blood pressure in obese young adults. Clin Exp Hypertens 2016;38(2):203-208. doi:10.3109/10641963.2015.1081219</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Eriguchi M, Yotsueda R, Torisu K et al. Assessment of urinary angiotensinogen as a marker of podocyte injury in proteinuric nephropathies. Am J Physiol Renal Physiol 2016;310(4):F322-F333.doi:10.1152/ajprenal.00260.2015</mixed-citation><mixed-citation xml:lang="en">Eriguchi M, Yotsueda R, Torisu K et al. Assessment of urinary angiotensinogen as a marker of podocyte injury in proteinuric nephropathies. Am J Physiol Renal Physiol 2016;310(4):F322-F333.doi:10.1152/ajprenal.00260.2015</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Burns Kevin D, Lytvyn Yuliya, Mahmud Farid H, Daneman Denis. The relationship between urinary renin-angiotensin system markers, renal function, and blood pressure in adolescents with type 1 diabetes. Am J Physiol Renal Physiol 2017; 312: F335–F342, doi:10.1152/ajprenal.00438.2016</mixed-citation><mixed-citation xml:lang="en">Burns Kevin D, Lytvyn Yuliya, Mahmud Farid H, Daneman Denis. The relationship between urinary renin-angiotensin system markers, renal function, and blood pressure in adolescents with type 1 diabetes. Am J Physiol Renal Physiol 2017; 312: F335–F342, doi:10.1152/ajprenal.00438.2016</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Hanène Ayari, Liliana Legedz, Catherine Cerutti et al. Mutual amplification of corticosteroids and angiotensin systems in human vascular smooth muscle cells and carotid atheroma. J Mol Med 2014; 92: 1201-1208</mixed-citation><mixed-citation xml:lang="en">Hanène Ayari, Liliana Legedz, Catherine Cerutti et al. Mutual amplification of corticosteroids and angiotensin systems in human vascular smooth muscle cells and carotid atheroma. J Mol Med 2014; 92: 1201-1208</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Luik PT, Kerstens MN, Hoogenberg K et al. Low plasma aldosterone despite normal plasma renin activity in uncomplicated type 1 diabetes mellitus: effects of RAAS stimulation. European Journal of Clinical Investigation 2003; 33: 787–793</mixed-citation><mixed-citation xml:lang="en">Luik PT, Kerstens MN, Hoogenberg K et al. Low plasma aldosterone despite normal plasma renin activity in uncomplicated type 1 diabetes mellitus: effects of RAAS stimulation. European Journal of Clinical Investigation 2003; 33: 787–793</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Massolini BD, Contieri SSG, Lazarini GS et al. Therapeutic Renin Inhibition in Diabetic Nephropathy-A Review of the Physiological Evidence. Front Physiol 2020 Mar 12;11:190. doi: 10.3389/fphys.2020.00190. PMID: 32231590; PMCID: PMC7082742</mixed-citation><mixed-citation xml:lang="en">Massolini BD, Contieri SSG, Lazarini GS et al. Therapeutic Renin Inhibition in Diabetic Nephropathy-A Review of the Physiological Evidence. Front Physiol 2020 Mar 12;11:190. doi: 10.3389/fphys.2020.00190. PMID: 32231590; PMCID: PMC7082742</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Schjoedt KJ, Jacobsen P, Rossing K et al. Dual Blockade of the Renin-angiotensin-aldosterone System in Diabetic Nephropathy: The Role of Aldosterone. Horm Metab Res 2005; 37, Supplement 1: 4-8. doi:10.1055/s-2005-861359 ´ ISSN 0018-5043</mixed-citation><mixed-citation xml:lang="en">Schjoedt KJ, Jacobsen P, Rossing K et al. Dual Blockade of the Renin-angiotensin-aldosterone System in Diabetic Nephropathy: The Role of Aldosterone. Horm Metab Res 2005; 37, Supplement 1: 4-8. doi:10.1055/s-2005-861359 ´ ISSN 0018-5043</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Fang H, Deng M, Zhang L, Lu A, Su J, Xu C, Zhou L, Wang L, Ou JS, Wang W, Yang T. Role of (pro)renin receptor in albumin overload- induced nephropathy in rats. Am J Physiol Renal Physiol. 2018 Dec 1;315(6):F1759-F1768. doi: 10.1152/ajprenal.00071.2018. Epub 2018 May 30. PMID: 29846109; PMCID: PMC6336996;</mixed-citation><mixed-citation xml:lang="en">Fang H, Deng M, Zhang L, Lu A, Su J, Xu C, Zhou L, Wang L, Ou JS, Wang W, Yang T. Role of (pro)renin receptor in albumin overload- induced nephropathy in rats. Am J Physiol Renal Physiol. 2018 Dec 1;315(6):F1759-F1768. doi: 10.1152/ajprenal.00071.2018. Epub 2018 May 30. PMID: 29846109; PMCID: PMC6336996;</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou L, Liu Y. Wnt/β-catenin signaling and renin-angiotensin system in chronic kidney disease. Curr Opin Nephrol Hypertens 2016 Mar;25(2):100-106. doi: 10.1097/MNH.0000000000000205.PMID: 26808707; PMCID: PMC4770891</mixed-citation><mixed-citation xml:lang="en">Zhou L, Liu Y. Wnt/β-catenin signaling and renin-angiotensin system in chronic kidney disease. Curr Opin Nephrol Hypertens 2016 Mar;25(2):100-106. doi: 10.1097/MNH.0000000000000205.PMID: 26808707; PMCID: PMC4770891</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Toshie Saito, Maki Urushihara, Yumiko Kotani et al. Increased Urinary Angiotensinogen Is Precedent to Increased Urinary Albumin in Patients With Type 1 Diabetes. The American Journal of the Medical Sciences 2009; 338(6):478-480</mixed-citation><mixed-citation xml:lang="en">Toshie Saito, Maki Urushihara, Yumiko Kotani et al. Increased Urinary Angiotensinogen Is Precedent to Increased Urinary Albumin in Patients With Type 1 Diabetes. The American Journal of the Medical Sciences 2009; 338(6):478-480</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Jandeleit-Dahm Karin, Cooper Mark E. Hypertension and Diabetes: Role of the Renin-Angiotensin System. Endocrinol Metab Clin N Am 2006; 35:469–490</mixed-citation><mixed-citation xml:lang="en">Jandeleit-Dahm Karin, Cooper Mark E. Hypertension and Diabetes: Role of the Renin-Angiotensin System. Endocrinol Metab Clin N Am 2006; 35:469–490</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Ye M, Wysocki J, William J et al. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensinconverting enzyme: Implications for albuminuria in diabetes. J Am Soc Nephrol 2006;17:3067–3075</mixed-citation><mixed-citation xml:lang="en">Ye M, Wysocki J, William J et al. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensinconverting enzyme: Implications for albuminuria in diabetes. J Am Soc Nephrol 2006;17:3067–3075</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Mendoza-Torres E, Oyarzún A, Mondaca-Ruff D et al. ACE2 and vasoactive peptides: novel players in cardiovascular/ renal remodeling and hypertension. Ther Adv Cardiovasc Dis 2015;9(4):217-237. doi:10.1177/1753944715597623</mixed-citation><mixed-citation xml:lang="en">Mendoza-Torres E, Oyarzún A, Mondaca-Ruff D et al. ACE2 and vasoactive peptides: novel players in cardiovascular/ renal remodeling and hypertension. Ther Adv Cardiovasc Dis 2015;9(4):217-237. doi:10.1177/1753944715597623</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Santos RAS, Sampaio WO, Alzamora AC et al. The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev 2018 Jan 1;98(1):505-553. doi: 10.1152/physrev.00023.2016. PMID: 29351514; PMCID: PMC7203574</mixed-citation><mixed-citation xml:lang="en">Santos RAS, Sampaio WO, Alzamora AC et al. The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev 2018 Jan 1;98(1):505-553. doi: 10.1152/physrev.00023.2016. PMID: 29351514; PMCID: PMC7203574</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Feng Q, Liu D, Lu Y, Liu Z. The Interplay of Renin-Angiotensin System and Toll-Like Receptor 4 in the Inflammation of Diabetic Nephropathy. J Immunol Res 2020 Apr 30;2020:6193407. doi: 10.1155/2020/6193407. PMID: 32411800; PMCID: PMC7210546</mixed-citation><mixed-citation xml:lang="en">Feng Q, Liu D, Lu Y, Liu Z. The Interplay of Renin-Angiotensin System and Toll-Like Receptor 4 in the Inflammation of Diabetic Nephropathy. J Immunol Res 2020 Apr 30;2020:6193407. doi: 10.1155/2020/6193407. PMID: 32411800; PMCID: PMC7210546</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia-Fernandez N, Jacobs-Cachá C, Mora-Gutiérrez JM et al. Matrix Metalloproteinases in Diabetic Kidney Disease. J Clin Med 2020 Feb 8;9(2):472. doi: 10.3390/jcm9020472. PMID: 32046355; PMCID: PMC7073625</mixed-citation><mixed-citation xml:lang="en">Garcia-Fernandez N, Jacobs-Cachá C, Mora-Gutiérrez JM et al. Matrix Metalloproteinases in Diabetic Kidney Disease. J Clin Med 2020 Feb 8;9(2):472. doi: 10.3390/jcm9020472. PMID: 32046355; PMCID: PMC7073625</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Шуцкая ЖВ, Башнина ЕБ, Савенкова НД. Распространенность диабетической нефропатии у больных с аллельными вариантами С677Т полиморфизма гена МТГФР по результатам 7-летнего катамнеза. Нефрология 2008;12(1):36-39 Shutskaya ZhV, Bashnina EB, Savenkova ND. Prevalence of diabetic nephropathy in patients with allelic variants OF the C677T gene polymorphism according to the results of 7-year catamnesis. Nephrology 2008;12(1):36-39</mixed-citation><mixed-citation xml:lang="en">Shutskaya ZhV, Bashnina EB, Savenkova ND. Prevalence of diabetic nephropathy in patients with allelic variants OF the C677T gene polymorphism according to the results of 7-year catamnesis. Nephrology 2008;12(1):36-39</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">McCrimmon RJ, Henry RR. SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia 2018; 61: 2126–2133</mixed-citation><mixed-citation xml:lang="en">McCrimmon RJ, Henry RR. SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia 2018; 61: 2126–2133</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Bjornstad P, Maahs DM, Jensen T et al. Elevated copeptin is associated with atherosclerosis and diabetic kidney disease in adults with type 1 diabetes. J Diabetes Complicat 2016; 30: 1093–1096</mixed-citation><mixed-citation xml:lang="en">Bjornstad P, Maahs DM, Jensen T et al. Elevated copeptin is associated with atherosclerosis and diabetic kidney disease in adults with type 1 diabetes. J Diabetes Complicat 2016; 30: 1093–1096</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Bjornstad P, Schafer M, Truong U et al. Metformin improves insulin sensitivity and vascular health in youth with type 1 diabetes mellitus. Circulation 2018; 138: 2895–2907</mixed-citation><mixed-citation xml:lang="en">Bjornstad P, Schafer M, Truong U et al. Metformin improves insulin sensitivity and vascular health in youth with type 1 diabetes mellitus. Circulation 2018; 138: 2895–2907</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Górriz JL, Soler MJ, Navarro-González JF et al. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. J Clin Med 2020 Mar 30;9(4):947. doi: 10.3390/jcm9040947. PMID: 32235471; PMCID: PMC7231090</mixed-citation><mixed-citation xml:lang="en">Górriz JL, Soler MJ, Navarro-González JF et al. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. J Clin Med 2020 Mar 30;9(4):947. doi: 10.3390/jcm9040947. PMID: 32235471; PMCID: PMC7231090</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Libianto R, Jerums G, Lam Q et al. Relationship between urinary sodium excretion and serum aldosterone in patients with diabetes in the presence and absence of modifiers of the renin–angiotensin–aldosterone system. Clinical Science.2014;126: 147–154 (Printed in Great Britain) doi: 10.1042/CS20130128</mixed-citation><mixed-citation xml:lang="en">Libianto R, Jerums G, Lam Q et al. Relationship between urinary sodium excretion and serum aldosterone in patients with diabetes in the presence and absence of modifiers of the renin–angiotensin–aldosterone system. Clinical Science.2014;126: 147–154 (Printed in Great Britain) doi: 10.1042/CS20130128</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Schernthaner Guntram. Kidney disease in diabetology: lessons from 2008. Nephrol Dial Transplant 2009; 24:396–399.doi: 10.1093/ndt/gfn694</mixed-citation><mixed-citation xml:lang="en">Schernthaner Guntram. Kidney disease in diabetology: lessons from 2008. Nephrol Dial Transplant 2009; 24:396–399. doi: 10.1093/ndt/gfn694</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Wysocki Jan, Goodling Anne, Burgaya Mar et al. Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease. Am J Physiol Renal Physiol 2017; 313: F487–F494</mixed-citation><mixed-citation xml:lang="en">Wysocki Jan, Goodling Anne, Burgaya Mar et al. Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease. Am J Physiol Renal Physiol 2017; 313: F487–F494</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Bjornstad P, Johnson RJ, Snell-Bergeon JK et al. Albuminuria is associated with greater copeptin concentrations in men with type 1 diabetes: a brief report from the T1D exchange Biobank. J Diabetes Complicat 2017; 31:387–389</mixed-citation><mixed-citation xml:lang="en">Bjornstad P, Johnson RJ, Snell-Bergeon JK et al. Albuminuria is associated with greater copeptin concentrations in men with type 1 diabetes: a brief report from the T1D exchange Biobank. J Diabetes Complicat 2017; 31:387–389</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson JJA, Couper JJ, Giles LC et al. Effect of metformin on vascular function in children with type 1 diabetes: a 12-month randomized controlled trial. J Clin EndocrinolMetab 2017; 102: 4448–4456</mixed-citation><mixed-citation xml:lang="en">Anderson JJA, Couper JJ, Giles LC et al. Effect of metformin on vascular function in children with type 1 diabetes: a 12-month randomized controlled trial. J Clin EndocrinolMetab 2017; 102: 4448–4456</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Catalá-López F, Macías Saint-Gerons D, González-Bermejo D et al. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. PLoS Med 2016 Mar 8;13(3):e1001971. doi: 10.1371/journal.pmed.1001971. Erratum in: PLoS Med. 2016 Jun;13(6):e1002064. PMID: 26954482; PMCID: PMC4783064</mixed-citation><mixed-citation xml:lang="en">Catalá-López F, Macías Saint-Gerons D, González-Bermejo D et al. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. PLoS Med 2016 Mar 8;13(3):e1001971. doi: 10.1371/journal.pmed.1001971. Erratum in: PLoS Med. 2016 Jun;13(6):e1002064. PMID: 26954482; PMCID: PMC4783064</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Marcovecchio ML, Chiesa ST, Bond S et al. ACE inhibitors and statins in adolescents with type 1 diabetes. NEngl JMed 2017; 377:1733–1745</mixed-citation><mixed-citation xml:lang="en">Marcovecchio ML, Chiesa ST, Bond S et al. ACE inhibitors and statins in adolescents with type 1 diabetes. NEngl JMed 2017; 377:1733–1745</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">American Diabetes Association. Standards of Medical Care in Diabetes-2018 Abridged for Primary Care Providers. Clin Diabetes 2018 Jan;36(1):14-37. doi: 10.2337/cd17-0119. PMID: 29382975; PMCID: PMC5775000</mixed-citation><mixed-citation xml:lang="en">American Diabetes Association. Standards of Medical Care in Diabetes-2018 Abridged for Primary Care Providers. Clin Diabetes 2018 Jan;36(1):14-37. doi: 10.2337/cd17-0119. PMID: 29382975; PMCID: PMC5775000</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Goenka L, Padmanaban R, George M. The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy. Curr Clin Pharmacol 2019;14(2):78-83. doi: 10.2174/1574884713666181116100946. PMID: 30444201; PMCID: PMC7011680;</mixed-citation><mixed-citation xml:lang="en">Goenka L, Padmanaban R, George M. The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy. Curr Clin Pharmacol 2019;14(2):78-83. doi: 10.2174/1574884713666181116100946. PMID: 30444201; PMCID: PMC7011680;</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Warren AM, Knudsen ST, Cooper ME. Diabetic nephropathy: An insight into molecular mechanisms and emerging therapies. Expert Opin Ther Targets 2019;23:579–591</mixed-citation><mixed-citation xml:lang="en">Warren AM, Knudsen ST, Cooper ME. Diabetic nephropathy: An insight into molecular mechanisms and emerging therapies. Expert Opin Ther Targets 2019;23:579–591</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Hanai K, Babazono T. CREDENCE: A silver lining in the dark cloud of diabetic nephropathy. 2020 May: 11 (3):527-529. doi: 10.1111 / jdi.13175. Epub 2019 Dec 4. PMID: 31705732; PMCID: PMC7232279</mixed-citation><mixed-citation xml:lang="en">Hanai K, Babazono T. CREDENCE: A silver lining in the dark cloud of diabetic nephropathy. 2020 May: 11 (3):527-529. doi: 10.1111 / jdi.13175. Epub 2019 Dec 4. PMID: 31705732; PMCID: PMC7232279</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
